Your browser doesn't support javascript.
Development of an inactivated vaccine candidate for SARS-CoV-2.
Gao, Qiang; Bao, Linlin; Mao, Haiyan; Wang, Lin; Xu, Kangwei; Yang, Minnan; Li, Yajing; Zhu, Ling; Wang, Nan; Lv, Zhe; Gao, Hong; Ge, Xiaoqin; Kan, Biao; Hu, Yaling; Liu, Jiangning; Cai, Fang; Jiang, Deyu; Yin, Yanhui; Qin, Chengfeng; Li, Jing; Gong, Xuejie; Lou, Xiuyu; Shi, Wen; Wu, Dongdong; Zhang, Hengming; Zhu, Lang; Deng, Wei; Li, Yurong; Lu, Jinxing; Li, Changgui; Wang, Xiangxi; Yin, Weidong; Zhang, Yanjun; Qin, Chuan.
  • Gao Q; Sinovac Biotech Ltd., Beijing, China.
  • Bao L; Key Laboratory of Human Disease Comparative Medicine, Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical
  • Mao H; Department of Microbiology, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
  • Wang L; Sinovac Biotech Ltd., Beijing, China.
  • Xu K; Division of Respiratory Virus Vaccines, National Institute for Food and Drug Control, Beijing, China.
  • Yang M; CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
  • Li Y; Sinovac Biotech Ltd., Beijing, China.
  • Zhu L; CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
  • Wang N; CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
  • Lv Z; CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
  • Gao H; Key Laboratory of Human Disease Comparative Medicine, Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical
  • Ge X; Sinovac Biotech Ltd., Beijing, China.
  • Kan B; National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Changping, Beijing, China.
  • Hu Y; Sinovac Biotech Ltd., Beijing, China.
  • Liu J; Key Laboratory of Human Disease Comparative Medicine, Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical
  • Cai F; Sinovac Biotech Ltd., Beijing, China.
  • Jiang D; Sinovac Biotech Ltd., Beijing, China.
  • Yin Y; Sinovac Biotech Ltd., Beijing, China.
  • Qin C; Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing, China.
  • Li J; Sinovac Biotech Ltd., Beijing, China.
  • Gong X; Sinovac Biotech Ltd., Beijing, China.
  • Lou X; Department of Microbiology, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
  • Shi W; Department of Microbiology, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
  • Wu D; Sinovac Biotech Ltd., Beijing, China.
  • Zhang H; Sinovac Biotech Ltd., Beijing, China.
  • Zhu L; Sinovac Biotech Ltd., Beijing, China.
  • Deng W; Key Laboratory of Human Disease Comparative Medicine, Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical
  • Li Y; Sinovac Biotech Ltd., Beijing, China.
  • Lu J; National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Changping, Beijing, China. qinchuan@pumc.edu.cn yjzhang@cdc.zj.cn yinwd@sinovac.com xiangxi@ibp.ac.cn changguili@aliyun.com lujinxing@icdc.cn.
  • Li C; Division of Respiratory Virus Vaccines, National Institute for Food and Drug Control, Beijing, China. qinchuan@pumc.edu.cn yjzhang@cdc.zj.cn yinwd@sinovac.com xiangxi@ibp.ac.cn changguili@aliyun.com lujinxing@icdc.cn.
  • Wang X; CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China. qinchuan@pumc.edu.cn yjzhang@cdc.zj.cn yinwd@sinovac.com xiangxi@ibp.ac.cn changguili@aliyun.com lujinxing@icdc.cn.
  • Yin W; Sinovac Biotech Ltd., Beijing, China. qinchuan@pumc.edu.cn yjzhang@cdc.zj.cn yinwd@sinovac.com xiangxi@ibp.ac.cn changguili@aliyun.com lujinxing@icdc.cn.
  • Zhang Y; Department of Microbiology, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China. qinchuan@pumc.edu.cn yjzhang@cdc.zj.cn yinwd@sinovac.com xiangxi@ibp.ac.cn changguili@aliyun.com lujinxing@icdc.cn.
  • Qin C; Key Laboratory of Human Disease Comparative Medicine, Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical
Science ; 369(6499): 77-81, 2020 07 03.
Article in English | MEDLINE | ID: covidwho-197649
ABSTRACT
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in an unprecedented public health crisis. Because of the novelty of the virus, there are currently no SARS-CoV-2-specific treatments or vaccines available. Therefore, rapid development of effective vaccines against SARS-CoV-2 are urgently needed. Here, we developed a pilot-scale production of PiCoVacc, a purified inactivated SARS-CoV-2 virus vaccine candidate, which induced SARS-CoV-2-specific neutralizing antibodies in mice, rats, and nonhuman primates. These antibodies neutralized 10 representative SARS-CoV-2 strains, suggesting a possible broader neutralizing ability against other strains. Three immunizations using two different doses, 3 or 6 micrograms per dose, provided partial or complete protection in macaques against SARS-CoV-2 challenge, respectively, without observable antibody-dependent enhancement of infection. These data support the clinical development and testing of PiCoVacc for use in humans.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Viral Vaccines / Coronavirus Infections / Antibodies, Neutralizing / Pandemics / Betacoronavirus / Antibodies, Viral Type of study: Prognostic study Topics: Vaccines Language: English Journal: Science Year: 2020 Document Type: Article Affiliation country: Science.abc1932

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Viral Vaccines / Coronavirus Infections / Antibodies, Neutralizing / Pandemics / Betacoronavirus / Antibodies, Viral Type of study: Prognostic study Topics: Vaccines Language: English Journal: Science Year: 2020 Document Type: Article Affiliation country: Science.abc1932